Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype.
Demina I, Zerkalenkova E, Illarionova O, Olshanskaya Y, Verzhbitskaya T, Semchenkova A, Tsaur G, Rusanova E, Belogurova M, Baidun L, Plyasunova S, Konyuhova T, Kazakova A, Fechina L, Novichkova G, Samochatova E, Myakova N, Maschan A, Popov AM. Demina I, et al. Among authors: verzhbitskaya t. J Cancer Res Clin Oncol. 2019 Nov;145(11):2803-2811. doi: 10.1007/s00432-019-03010-1. Epub 2019 Aug 28. J Cancer Res Clin Oncol. 2019. PMID: 31463716
Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia.
Popov A, Henze G, Verzhbitskaya T, Roumiantseva J, Lagoyko S, Khlebnikova O, Streneva O, Bidanov O, Tsaur G, Inaba H, Karachunskiy A, Fechina L. Popov A, et al. Among authors: verzhbitskaya t. J Cancer Res Clin Oncol. 2019 May;145(5):1331-1339. doi: 10.1007/s00432-019-02886-3. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840196
Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols.
Popov A, Buldini B, De Lorenzo P, Disarò S, Verzhbitskaya T, Movchan L, Giarin E, Shorikov E, Di Meglio A, Tsaur G, Parasole R, Miakova N, Boichenko E, Kondratchik K, Aleinikova O, Karachunskiy A, Roumiantsev A, Locatelli F, Biondi A, Pieters R, Valsecchi MG, Fechina L, Basso G. Popov A, et al. Among authors: verzhbitskaya t. Leukemia. 2020 Nov;34(11):3042-3046. doi: 10.1038/s41375-020-0912-z. Epub 2020 Jun 12. Leukemia. 2020. PMID: 32533093 No abstract available.
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G, Popov A, Riger T, Kustanovich A, Solodovnikov A, Shorikov E, Demina A, Verzhbitskaya T, Streneva O, Makarova O, Lapotentova E, Aleinikova O, Miakova N, Boichenko E, Kondratchik K, Ponomareva N, Karachunskiy A, Roumiantsev A, Fechina L. Tsaur G, et al. Among authors: verzhbitskaya t. Br J Haematol. 2021 Jun;193(6):1151-1156. doi: 10.1111/bjh.17304. Epub 2021 Feb 14. Br J Haematol. 2021. PMID: 33583020 Clinical Trial.
Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
Permikin Z, Popov A, Verzhbitskaya T, Riger T, Plekhanova O, Makarova O, Froňková E, Trka J, Meyer C, Marschalek R, Tsaur G, Fechina L. Permikin Z, et al. Among authors: verzhbitskaya t. Leuk Res. 2022 Jan;112:106758. doi: 10.1016/j.leukres.2021.106758. Epub 2021 Nov 25. Leuk Res. 2022. PMID: 34864370 No abstract available.
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Popov A, Tsaur G, Verzhbitskaya T, Riger T, Permikin Z, Demina A, Mikhailova E, Shorikov E, Arakaev O, Streneva O, Khlebnikova O, Makarova O, Miakova N, Fominikh V, Boichenko E, Kondratchik K, Ponomareva N, Novichkova G, Karachunskiy A, Fechina L. Popov A, et al. Among authors: verzhbitskaya t. Br J Haematol. 2023 May;201(3):510-519. doi: 10.1111/bjh.18021. Epub 2021 Dec 30. Br J Haematol. 2023. PMID: 34970734
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: verzhbitskaya t. Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23. Leukemia. 2022. PMID: 35322171 No abstract available.
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A, Mikhailova E, Komkov A, Gaskova M, Abasov R, Matveev E, Kazanov M, Mamedov I, Shmitko A, Belova V, Miroshnichenkova A, Illarionova O, Olshanskaya Y, Tsaur G, Verzhbitskaya T, Ponomareva N, Bronin G, Kondratchik K, Fechina L, Diakonova Y, Vavilova L, Myakova N, Novichkova G, Maschan A, Maschan M, Zerkalenkova E, Popov A. Semchenkova A, et al. Among authors: verzhbitskaya t. Int J Mol Sci. 2022 Apr 5;23(7):4019. doi: 10.3390/ijms23074019. Int J Mol Sci. 2022. PMID: 35409391 Free PMC article.
21 results